🟢 Telix Pharmaceuticals is trading 4.17% up today ahead of FDA’s September 11 Pixclara decision

Telix Pharmaceuticals is trading 4.17% up at $12.48 as investors focus on the FDA’s September 11 decision deadline for Pixclara, its brain-cancer imaging agent.

• Recent coverage says shares have climbed as that regulatory decision approaches.
• Telix announced September 9 conference presentations.
• The broader market and healthcare sector are weaker, suggesting company-specific FDA anticipation is outweighing negative macro and sector sentiment.